Links & Summaries to 7 new Hepatitis C Articles

[Guest guest]

Gilead Amends HCV Combo Study

InvestorIdeas.com (press release)

Gilead is hoping to build one of the largest hepatitis C pipelines with six

compounds in clinical development. Moreover Gilead is also developing

proprietary drug combinations which aim to reduce treatment duration to 12-16

weeks and spare the use of ...

See all stories on this topic »Fresno Needle Exchange Program Presses On

KSEE

The goal is to prevent the spread of diseases like HIV and hepatitis C. Director

Dallas Blanchard says it also protects the community. " When a law enforcement

officer comes in contact with someone who has needles, they're properly

containerized and ...

See all stories on this topic »Santaris Pharma A/S Showcases microRNA and mRNA

Research Advancements ...

MarketWatch (press release)

" The Company is providing an update on the progress of its lead

microRNA-targeted drug candidate, miravirsen, for the treatment of Hepatitis C;

presenting data on the use of Santaris Pharma A/S proprietary 'tiny' LNA-based

drugs to inhibit entire ...

See all stories on this topic »New Treatment Options Are On The Horizon For

People Co-Infected With HIV And ...

The AIDS Beacon

According to a recent review, the new hepatitis C treatment options Victrelis

and Incivek may soon be available for people with HIV and hepatitis C. In the

meantime, the authors suggested that strategies be developed to optimize

management of hepatitis ...

See all stories on this topic »

Progress in Hepatitis C research

Baltimore Sun

By Meredith Cohn, The Baltimore Sun Hepatitis C has long been a problem with a

low rate of cure. But new drug therapies are in use and others are on the

horizon, according to Dr. J. Thuluvath, chief of gastroenterology at Mercy

Medical Center and ...

See all stories on this topic »Pharmasset climbs after study result released

BusinessWeek

By AP Drug developer Pharmasset Inc. hit a " home run " with results from a

mid-stage study of a potential hepatitis C virus treatment, according to a Citi

analyst. THE SPARK: Pharmasset, based in Princeton, NJ, said Tuesday results

from a study of the ...

See all stories on this topic »Anadys' Setrobuvir Named One of Windhover's Top

10 Most Interesting Infectious ...

MarketWatch (press release)

" This recognition reflects the scarcity of later-stage development assets in

hepatitis C and the strong desire on the part of companies to assemble

combination regimens to treat this disease. With a readout next month of the

12-week data from an ...

See all stories on this topic »

[Guest guest]

Gilead Amends HCV Combo Study

InvestorIdeas.com (press release)

Gilead is hoping to build one of the largest hepatitis C pipelines with six

compounds in clinical development. Moreover Gilead is also developing

proprietary drug combinations which aim to reduce treatment duration to 12-16

weeks and spare the use of ...

See all stories on this topic »Fresno Needle Exchange Program Presses On

KSEE

The goal is to prevent the spread of diseases like HIV and hepatitis C. Director

Dallas Blanchard says it also protects the community. " When a law enforcement

officer comes in contact with someone who has needles, they're properly

containerized and ...

See all stories on this topic »Santaris Pharma A/S Showcases microRNA and mRNA

Research Advancements ...

MarketWatch (press release)

" The Company is providing an update on the progress of its lead

microRNA-targeted drug candidate, miravirsen, for the treatment of Hepatitis C;

presenting data on the use of Santaris Pharma A/S proprietary 'tiny' LNA-based

drugs to inhibit entire ...

See all stories on this topic »New Treatment Options Are On The Horizon For

People Co-Infected With HIV And ...

The AIDS Beacon

According to a recent review, the new hepatitis C treatment options Victrelis

and Incivek may soon be available for people with HIV and hepatitis C. In the

meantime, the authors suggested that strategies be developed to optimize

management of hepatitis ...

See all stories on this topic »

Progress in Hepatitis C research

Baltimore Sun

By Meredith Cohn, The Baltimore Sun Hepatitis C has long been a problem with a

low rate of cure. But new drug therapies are in use and others are on the

horizon, according to Dr. J. Thuluvath, chief of gastroenterology at Mercy

Medical Center and ...

See all stories on this topic »Pharmasset climbs after study result released

BusinessWeek

By AP Drug developer Pharmasset Inc. hit a " home run " with results from a

mid-stage study of a potential hepatitis C virus treatment, according to a Citi

analyst. THE SPARK: Pharmasset, based in Princeton, NJ, said Tuesday results

from a study of the ...

See all stories on this topic »Anadys' Setrobuvir Named One of Windhover's Top

10 Most Interesting Infectious ...

MarketWatch (press release)

" This recognition reflects the scarcity of later-stage development assets in

hepatitis C and the strong desire on the part of companies to assemble

combination regimens to treat this disease. With a readout next month of the

12-week data from an ...

See all stories on this topic »